

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/apm-21-2023	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	We will share the HPD rate of patients with primary liver cancer treated with ICI. And we found that lung metastasis and lymph node metastasis are independent risk factors for HPD.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol, statistical analysis plan will be shared.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique may be updated over time.
7	To whom will you share the data?	Oncologists and infection physicians who are interested in primary liver cancer and HPD research.
8	For what type of analysis or purpose?	To figure out the reality of HPD rate in patients with primary liver cancer receiving ICI therapy and to analysis the risk factors.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: liuli@i.smu.edu.cn
10	Any other restrictions?	We may balance the potential benefits and risks for each reasonable request, and then establish data sharing collaboration after our hospital's ethical application.